GLYC News and Press, GlycoMimetics Inc. From 03/16/22

Data delay for AML therapy is most likely due to a positive OS trend. Uproleselan AML trial is fully enrolled with data due in 2023. GlycoMimetics is woefully undervalued, but not without risk. For further details see: GlycoMimetics Positive Data For AML Therapy Increasi...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the Company will participate at the 34 th Annual Roth Conference in Laguna Niguel, California, March 14 and 15. Chief Executive Officer Harout Semerjian and Chief Financial Officer Brian Hahn will attend in person. Rese...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

GlycoMimetics (NASDAQ:GLYC) has filed for a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for working capital, capital expenditures and general corporate purposes. The offer...

Image source: The Motley Fool. GlycoMimetics (NASDAQ: GLYC) Q4 2021 Earnings Call Mar 03, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: GlycoMimetics (GLYC) Q4 2021 Earnings Call Transcript

GlycoMimetics, Inc. (GLYC) Q4 2021 Earnings Conference Call March 3, 2022 8:30 AM ET Company Participants Shari Annes - IR Harout Semerjian - President and Chief Executive Officer Brian Hahn - SVP and Chief Financial Officer Armand Girard - Chief Business Officer, SVP Strategy and Corporate D...

GlycoMimetics press release (NASDAQ:GLYC): Q4 GAAP EPS of -$0.33 beats by $0.01. Revenue of $0.18M (+12.5% Y/Y). For further details see: GlycoMimetics GAAP EPS of -$0.33 beats by $0.01, revenue of $0.18M

Post year-end 2022 remains target for top-line data release of GlycoMimetics-sponsored pivotal Phase 3 trial evaluating uproleselan in relapsed/refractory acute myeloid leukemia (AML) National Cancer Institute (NCI) to conduct post-Phase 2 interim analysis based on event-fre...

GlycoMimetics (NASDAQ:GLYC) is scheduled to announce Q4 earnings results on Thursday, March 3rd, before market open. The consensus EPS Estimate is -$0.34 Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. For further details see: GlycoMimetics Q4 2021 Ear...

ABUS, ARGX, ASPS, ATRS, BBY, BF.B, BIG, BILI, BJ, BURL, CAN, CNCE, CNQ, CNSL, CPG, CRH, OTCQX:DLAKF, EYPT, GLYC, GOGO, GRAB, HTOO, KR, MBT, MCS, MEI, OTCPK:MKGAF, MTLS, OXSQ, REE, REV, SBSW, OTCPK:SNCAF, SOHO, SRLP, STXS, SUP, TD, TGLS, TTC, TTSH, TWI, TZOO, UONE, UTZ, WB, WHF, WVE For Seekin...